Spyre Therapeutics, Inc.
SYRE- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001636282
In the last 90 days, Spyre Therapeutics, Inc. insiders filed 0 open-market purchases and 9 sales; 265 institutions reported holding it in 13F filings for Q2 2026, worth $8.52B in total; no superinvestor holds it.
13F holders, Q1 2026
Institutional positions in Spyre Therapeutics, Inc. as of Mar 31, 2026. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 198
- +47 vs. Q4 2025
- Shares held
- 82.7M
- +5.74M (+7.5%) vs. Q4 2025
- Total value
- $4.16B
- +$1.64B (+65.2%) vs. Q4 2025
- New holders
- 58
- 67 more added
- Sold out
- 11
- 49 more reduced
2 institutions that held it in Q4 2025 haven't filed for Q1 2026 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q4 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting SYRE on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 265 | $8.52B |
| Q1 2026 | 198 | $4.16B |
| Q4 2025 | 153 | $2.65B |
| Q3 2025 | 137 | $1.08B |
| Q2 2025 | 129 | $952.6M |
| Q1 2025 | 129 | $1.00B |
| Q4 2024 | 131 | $1.39B |
| Q3 2024 | 119 | $1.51B |
| Q2 2024 | 107 | $1.18B |
| Q1 2024 | 103 | $1.21B |
| Q4 2023 | 54 | $601.0M |
| Q3 2023 | 29 | $43.9M |
| Q2 2023 | 44 | $31.9M |
| Q1 2023 | 45 | $12.0M |
| Q4 2022 | 51 | $19.2M |
| Q3 2022 | 55 | $23.5M |
| Q2 2022 | 67 | $24.8M |
| Q1 2022 | 84 | $95.4M |
| Q4 2021 | 86 | $189.4M |
| Q3 2021 | 77 | $322.5M |
| Q2 2021 | 78 | $285.8M |
| Q1 2021 | 84 | $328.7M |
Institutions, Q1 2026
Shares, value and share of portfolio for each institution holding Spyre Therapeutics, Inc.; share changes are against Q4 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Parkman Healthcare Partners LLC | 0 | $0 | 0.00% | −124,485−100.0% | Sold out |
| Optimize Financial Inc | 0 | $0 | 0.00% | −25,331−100.0% | Sold out |
| Caxton Corp | 0 | $0 | 0.00% | −8,919−100.0% | Sold out |
| VARCOV Co. | 0 | $0 | 0.00% | −8,008−100.0% | Sold out |
| Brevan Howard Capital Management LP | 0 | $0 | 0.00% | −6,198−100.0% | Sold out |
| Quest Partners LLC | 0 | $0 | 0.00% | −3,538−100.0% | Sold out |
| Amalgamated Bank | 0 | $0 | 0.00% | −2,165−100.0% | Sold out |
| Daiwa Securities Group Inc. | 0 | $0 | 0.00% | −258−100.0% | Sold out |
| Meeder Asset Management Inc | 0 | $0 | 0.00% | −181−100.0% | Sold out |
| Vanguard Group Inc | – | – | – | – | Not filed |
| Comerica Bank | – | – | – | – | Not filed |